Sage Capital hit by biotech and tech bets amid volatile ASX earnings season
Australian hedge fund manager Sage Capital saw both of its flagship strategies lag benchmarks in August, as high-conviction positions in Telix Pharmaceuticals and WiseTech Global dragged on performance during what it called one of the most volatile earnings seasons on
